Q4 EPS Estimate for Knight Therapeutics Lowered by Analyst

Knight Therapeutics Inc. (TSE:GUD) – Investment analysts at Stifel Canada cut their Q4 2024 earnings per share (EPS) estimates for shares of Knight Therapeutics in a research note issued on Thursday, November 7th. Stifel Canada analyst J. Keywood now forecasts that the company will earn $0.06 per share for the quarter, down from their prior forecast of $0.07. Stifel Canada has a “Strong-Buy” rating on the stock. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share.

Separately, Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the company from C$5.75 to C$6.75 in a research report on Tuesday, August 13th.

Knight Therapeutics Stock Down 1.2 %

Shares of TSE:GUD opened at C$5.11 on Monday. The company has a market capitalization of C$517.18 million, a PE ratio of -25.55, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. The business has a fifty day moving average price of C$5.73 and a two-hundred day moving average price of C$5.74. Knight Therapeutics has a 1 year low of C$4.98 and a 1 year high of C$6.23.

Insider Activity

In other news, Senior Officer Amal Khouri sold 5,000 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of C$5.78, for a total transaction of C$28,919.00. In related news, Director Samira Sakhia acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of C$5.15 per share, with a total value of C$103,000.00. Also, Senior Officer Amal Khouri sold 5,000 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of C$5.78, for a total value of C$28,919.00. Insiders have sold 305,500 shares of company stock valued at $1,870,794 in the last 90 days. Insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.